• Lilly eyes more cancer deals, but wary of CAR-T, gene therapy firstwordpharma
    January 13, 2019
    Eli Lilly CEO Dave Ricks said that as the company looks for deals to enhance its pipeline of future treatments it will leave CAR-T therapies for cancer and gene therapy for rare diseases to others, as reported Yahoo Finance Friday.
PharmaSources Customer Service